- Coalition of healthcare industry stakeholders address best practices regarding controlled substances
- EXPERT BLOG: Provider status for pharmacists — one way or another
- Vitals predicts consumer healthcare trends for 2014
- Rite Aid Health Alliance aims at strengthening patient engagement
- Walgreens' corporate operations VP tapped to lead health care for Boots in U.K. and Ireland
ORLANDO, Fla. — Companies that lower co-payments on prescription drugs while promoting disease management can lower their own healthcare costs, according to a three-year study commissioned by the Florida Health Care Coalition and published in the journal Health Affairs.
The study, which focused on patients with diabetes, found that companies combining disease-management programs with “value-based insurance design” can earn a return of $1.33 for every dollar they spend upfront on medication.
“Amid soaring healthcare costs, this validates that old saying that an ounce of prevention is worth a pound of cure, and that’s especially true where it often hurts most: in our pocketbooks,” FHCC president and CEO Becky Cherney said.